AbbVie’s blockbuster drug Humira topped a list of eight drugs with price hikes that elevated U.S. health care spending by $1.3 billion in 2022 despite lack of new evidence supporting their health benefits, according to the drug price watchdog Institute for Clinical and Economic Review’s (ICER) latest yearly report. The annual report, examining price increases it says are not backed by clinical data, identified AbbVie's rheumatoid arthritis drug Humira as the primary contributor. The drug's exclusive patent protection last year...